{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-008901","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.211210+00:00","generated_at":"2026-06-07T11:22:27.697967+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DSMB recommends CNS Pharma's Berubicin trial continue unmodified after interim analysis","bullets":["DSMB recommended continuation of Berubicin vs. Lomustine Phase 2/3 trial in recurrent GBM based on comparable overall survival.","Enrollment expected to complete early Q1 2024; primary endpoint is overall survival.","CEO John Climaco stated recommendation reflects acceptable efficacy and safety as defined in protocol.","FDA has granted Fast Track and Orphan Drug Designation for Berubicin for malignant glioma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-008901","json":"https://secwatch.observer/filing/0001683168-23-008901.json","markdown":"https://secwatch.observer/filing/0001683168-23-008901.md","text":"https://secwatch.observer/filing/0001683168-23-008901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823008901/0001683168-23-008901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316823008901/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:22:27.697967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}